Details
Stereochemistry | ACHIRAL |
Molecular Formula | 6Al.2Bi.12O |
Molecular Weight | 771.8428 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Bi+3].[Bi+3]
InChI
InChIKey=PDSAKIXGSONUIX-UHFFFAOYSA-N
InChI=1S/6Al.2Bi.12O/q8*+3;12*-2
Molecular Formula | Al |
Molecular Weight | 26.9815 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | HO |
Molecular Weight | 17.0073 |
Charge | -1 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Bi |
Molecular Weight | 208.9804 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Bismuth aluminate is an antacid drug. The good therapeutic results are due to a coating effect providing a local antipepsin action at the site of the ulcer is an interesting possibility. Inorganic bismuth derivatives have good antibacterial properties and are considered to be only slightly toxic to humans because of their low uptake into human cells. The formation of methylated bismuth derivatives in the human gut may damage mammalian cells as well as the physiological gut microbiota.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/29636776
Curator's Comment: Known to be CNS penetrant in rat. Human data not available.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Coating of the mucosa Sources: https://www.ncbi.nlm.nih.gov/pubmed/14295334 |
|||
Target ID: Peptic activity Sources: https://www.ncbi.nlm.nih.gov/pubmed/14295334 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | Estomul Approved UseUnknown |
|||
Palliative | Estomul Approved UseUnknown |
|||
Palliative | Estomul Approved UseUnknown |
|||
Palliative | Estomul Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
ACTION OF BISMUTH ALUMINATE. | 1965 Jun 26 |
|
Further experience with bismuth aluminate in peptic ulceration and nervous dyspepsia. | 1965 Oct |
|
An evaluation of a bismuth aluminate antacid. | 1968 Mar |
|
[Formation of bismuth aluminate film on the gastric mucosa]. | 1972 |
|
[Bismuth aluminate in gastroenterology. Therapeutic effects in chronic erosive Campylobacter pylori-associated gastritis]. | 1989 Oct 10 |
|
Monitoring and evaluating the quality consistency of Compound Bismuth Aluminate tablets by a simple quantified ratio fingerprint method combined with simultaneous determination of five compounds and correlated with antioxidant activities. | 2015 |
|
Efficacy and Safety of Wei Bi Mei, a Chinese Herb Compound, as an Alternative to Bismuth for Eradication of Helicobacter pylori. | 2018 |
|
Preparation and cytocompatibility of a novel bismuth aluminate/calcium phosphate cement with high radiopacity. | 2018 Sep 4 |
Patents
Sample Use Guides
Liquid and tablets:
1 or 2 tablespoons or 1 or 2 tablets three times daily depending on severity of involvement.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13502848
Bismuth aluminate powder by Brindle’s method neutralises 70-88 per cent of acid in 20 minutes without an abnormal increase in pH and in therapeutic doses (0.7 g Bi).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:44:41 GMT 2023
by
admin
on
Fri Dec 15 15:44:41 GMT 2023
|
Record UNII |
JB5Y63JDHJ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CFR |
21 CFR 331.11
Created by
admin on Fri Dec 15 15:44:41 GMT 2023 , Edited by admin on Fri Dec 15 15:44:41 GMT 2023
|
||
|
CFR |
21 CFR 331.15
Created by
admin on Fri Dec 15 15:44:41 GMT 2023 , Edited by admin on Fri Dec 15 15:44:41 GMT 2023
|
||
|
NCI_THESAURUS |
C29701
Created by
admin on Fri Dec 15 15:44:41 GMT 2023 , Edited by admin on Fri Dec 15 15:44:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL2109110
Created by
admin on Fri Dec 15 15:44:41 GMT 2023 , Edited by admin on Fri Dec 15 15:44:41 GMT 2023
|
PRIMARY | |||
|
JB5Y63JDHJ
Created by
admin on Fri Dec 15 15:44:41 GMT 2023 , Edited by admin on Fri Dec 15 15:44:41 GMT 2023
|
PRIMARY | |||
|
40762
Created by
admin on Fri Dec 15 15:44:41 GMT 2023 , Edited by admin on Fri Dec 15 15:44:41 GMT 2023
|
PRIMARY | RxNorm | ||
|
76972018
Created by
admin on Fri Dec 15 15:44:41 GMT 2023 , Edited by admin on Fri Dec 15 15:44:41 GMT 2023
|
PRIMARY | |||
|
235-552-3
Created by
admin on Fri Dec 15 15:44:41 GMT 2023 , Edited by admin on Fri Dec 15 15:44:41 GMT 2023
|
PRIMARY | |||
|
C83557
Created by
admin on Fri Dec 15 15:44:41 GMT 2023 , Edited by admin on Fri Dec 15 15:44:41 GMT 2023
|
PRIMARY | |||
|
C065544
Created by
admin on Fri Dec 15 15:44:41 GMT 2023 , Edited by admin on Fri Dec 15 15:44:41 GMT 2023
|
PRIMARY | |||
|
12284-76-3
Created by
admin on Fri Dec 15 15:44:41 GMT 2023 , Edited by admin on Fri Dec 15 15:44:41 GMT 2023
|
PRIMARY | |||
|
SUB13079MIG
Created by
admin on Fri Dec 15 15:44:41 GMT 2023 , Edited by admin on Fri Dec 15 15:44:41 GMT 2023
|
PRIMARY | |||
|
100000076844
Created by
admin on Fri Dec 15 15:44:41 GMT 2023 , Edited by admin on Fri Dec 15 15:44:41 GMT 2023
|
PRIMARY | |||
|
m1031
Created by
admin on Fri Dec 15 15:44:41 GMT 2023 , Edited by admin on Fri Dec 15 15:44:41 GMT 2023
|
PRIMARY | Merck Index |